Shire Looks To Quash Mylan's Generic Colitis Drug

Law360, New York (May 30, 2012, 3:49 PM EDT) -- Irish pharmaceutical company Shire Development LLC on Monday hit Mylan Pharmaceuticals Inc. with a patent suit in Florida federal court, launching another attack against a generic-drug maker attempting to produce its own version of the ulcerative colitis drug Lialda.

Shire filed its complaint in the Middle District of Florida, claiming that Mylan had infringed U.S. Patent Number 6,773,720 by filing an abbreviated new drug application with the U.S. Food and Drug Administration for a generic version of Lialda.

Mylan sent letters to Shire on April 12,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.